CLDN18 and cancer: Immunostaining patterns of CDH17 and CLDN18 were investigated in whole sections of cancer tissue from representative cases (9 cases for CDH17 and 5 cases for CLDN18), including primary tumors and nodal metastases to remove some of the focal biases of TMAs (Figure 4).